Drug Development Congress
22nd-23rd April 2010, London, United Kingdom
Drug Development Congress is administered by Osney Media.
Next Event
2 day conference Industry Delegate fee (Not including VAT)
Thursday 22nd April 2010 to Friday 23rd April 2010
London, United Kingdom
More
Solution Providers
Oxford Global conferences’ strict delegate screening criteria and one to one meeting selection facility allow you to reach a large number of pre-qualified Drug Development decision makers and make the most of your time at the event.
Read More
Speakers
The Drug Development Congress consists of a unique blend of presentations, panel discussions and one to one business meetings. If you have a cutting edge case study or a thought provoking presentation join us at the event.
Read More
Speakers from

Ablynx

ActoGeniX NV

Aepodia

Aicuris

Almac

Aperio

AstraZeneca

Axxam S.p.A.

Basel

Baxter

Bayer Healthcare

Bayer-Schering Pharma

bioXell

Bristol Myers Squibb

Eli Lilly

Eisai

F. Hoffmann-La Roche

GlaxoSmithKline

GSK Biologics

Horizon Discovery

Human Genome Sciences

In-Motion Management

Maccine

MediGene AG

MedImmune

Merck KGaA

Metabolys

NNIT A/S

Novartis

Nycomed

Pfizer

Roche Products Ltd

Teva Pharmaceutical Industries

Tibotec-Virco

The Psychological Society

University of London

Wyeth

YM Biosciences

Featured Speakers
Wolfgang M. Baiker,
Corporate Head of Development, Boehringer Ingelheim
James Bailey,
GSK Team Leader, Medicinal Chemsitry, GSK
Sophie Banzet,
Head of Safety Science CNS, Roche
Mireille Cantarini,
Internal Clinical genetics Expert, Astrazeneca
Thomas Colatsky,
Director Division of Applied Pharmacology Research and Acting Director Laboratory of Clinical Pharmacology, FDA
Lucette Doessegger,
Global Head Safety Licensing and Early Development, Roche
Martin Elmlinger,
Director Biomarkers, Nycomed
Angela, Flannery
Director, R&D Science Policy, Astrazeneca
Dr. Thomas Herget,
Senior Director R&D New Technology Evaluation Performance & Life Science Chemicals, Merck
Vicki Ikin,
Clinical Biomarker Scientist Group Manager, Astrazeneca
Bahija Jallal,
VP Translational Sciences, Medimmune
Jörg Kemkowski,
Vice President, Head of Institute of Pharmcology and Preclinical Drug Safety (IPAS), Nycomed GmbH
Farhad Khan,
Principal Scientist in Epidemiology, Novo Nordisk A/S
Roy Mansfield,
Director Safety and Risk Management, Pfizer
Dr. Julian C. Matthews,
Senior Lecturer in the School of Cancer and Imaging Sciences, University of Manchester
Howard Mellor,
Pre-Clinical Safety Scientist, General Toxicology Sciences, Safety Assessment UK, Astrazeneca
Alan, Morrison
VP International Regulatory Affairs, Amgen
David Nicholson,
SVP Global Research, Schering Plough
Taoufik Outas,
Senior Scientist - Exploratory Development Department, Astellas
Elke Persohn,
Head of Cellular Imaging Group, Novartis
Stefan Platz,
Head Toxicology and Global Head Early Safety, Hoffman la Roche
Marc Princivalle,
Director of Toxicology, Research and Preclinical Development & Head of Preclinical Rish Assessment, EMEA, Stiefel (GSK)
Eugenii Rabiner,
Director, Clinical Imaging Applications, GSK
Tino Rossi,
VP Preclinical Drug Discovery & Enabling Technologies, Neurosciences CEDD, GlaxoSmithKline
Thomas Steinbach,
Senior Director Safety Surveillance & Risk Management, Wyeth
Jean-Pierre, Valetin,
Director, Safety Pharmacology, Astrazeneca
Philippe Van der Auwera,
Global Head of Safety, Roche
Jingsong Wang,
Director Discovery Medicine & Clinical Pharmacology, Bristol Myers Squibb
Will Watson,
Senior Partnering Director, Teva Innovative ventures
Agnes Westelinck.
Regulatory Affairs, Roche
Home | About The Event |  | Event Format | Speakers | Delegates | Solution Providers | Media Partners | Press Centre | Venue | Organisers | Other Events | Contact | Book Online | 
© Drug Development Congress